Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Jun 7

PMID 34093837

Citations 6

Authors

Laith Al-Showbaki

Michelle B Nadler

Alexandra Desnoyers

Fahad A Almugbel

David W Cescon

Eitan Amir

Affiliations

Soon will be listed here.

Abstract

Multiple anti-PD-1/PD-L1 antibodies have been approved, and in some diseases, there is a choice of more than one. Comparative efficacy, safety and tolerability are unknown. Randomized trials (RCTs) supporting the registration of single agent anti-PD1 or anti-PDL1 inhibitors between 2015-2019 were identified. We extracted the hazard ratio (HR) for overall survival (OS) and calculated the odds ratio (OR) for commonly reported safety and tolerability outcomes. We then performed a network meta-analysis, reporting multiple pair-wise comparisons between different anti-PD-1/PD-L1 antibodies. Sixteen RCTs comprising 10673 patients were included; 10 in non-small-cell lung cancer, 2 in melanoma, 2 in head and neck squamous cell carcinoma and 2 in urothelial cancer. Compared to pembrolizumab, efficacy was similar for nivolumab (HR: 1.02 95% CI: 0.91-1.14) and for atezolizumab (HR: 0.97 95% CI: 0.85-1.10), however, avelumab appeared inferior (HR: 1.30, 95% CI: 1.06-1.56). Pembrolizumab showed similar odds of serious adverse events (SAEs) as nivolumab (OR: 1.12, 95% CI: 0.56-2.27) and atezolizumab (OR: 1.05, 95% CI: 0.55-2.04). Compared to nivolumab, atezolizumab was associated with more SAEs (OR: 2.14, 95% CI: 1.47-3.12). Avelumab had the lowest odds of grade 3-4 adverse events compared to pembrolizumab (OR: 0.42, 95% CI: 0.24-0.74), nivolumab (OR: 0.38, 95% CI: 0.24-0.62) and atezolizumab (OR: 0.21, 95% CI: 0.14-0.33). The odds of treatment discontinuation without progression were similar between nivolumab and atezolizumab (OR: 1.20, 95% CI: 0.73-2.00), and between pembrolizumab and nivolumab (OR: 1.35, 95% CI: 0.83-2.17), but was higher with atezolizumab compared to nivolumab (OR: 2.56, 95% CI: 1.29-5.00). Pembrolizumab was associated with higher OR of immune-related adverse events (IRAEs) compared to nivolumab (OR: 2.12, 95% CI: 1.49-3.03) and atezolizumab (OR: 1.63, 95% CI: 1.09-2.43). Pembrolizumab, nivolumab, and atezolizumab have similar efficacy. Avelumab appears less efficacious. Safety and tolerability seem better with avelumab, but worse with atezolizumab and pembrolizumab.

Citing Articles

Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.

Becker J, Stang A, Schrama D, Ugurel S Am J Clin Dermatol. 2024; 25(4):541-557.

PMID: 38649621 PMC: 11193695. DOI: 10.1007/s40257-024-00858-z.

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.

Shen J, Choi Y, Lee T, Kim H, Chae Y, Dulken B J Immunother Cancer. 2024; 12(2).

PMID: 38355279 PMC: 10868175. DOI: 10.1136/jitc-2023-008339.

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival.

Lohray R, Verma K, Wang L, Haynes D, Lewis D Pragmat Obs Res. 2023; 14:149-154.

PMID: 38021416 PMC: 10658947. DOI: 10.2147/POR.S398151.

Selection of a PD-1 blocking antibody from a novel fully human phage display library.

Peissert F, Pluss L, Giudice A, Ongaro T, Villa A, Elsayed A Protein Sci. 2022; 31(12):e4486.

PMID: 36317676 PMC: 9667898. DOI: 10.1002/pro.4486.

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.

Thuru X, Magnez R, El-Bouazzati H, Vergoten G, Quesnel B, Bailly C Cancers (Basel). 2022; 14(14).

PMID: 35884428 PMC: 9322126. DOI: 10.3390/cancers14143368.

References

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F . Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018; 19(11):1468-1479. DOI: 10.1016/S1470-2045(18)30673-9. View

Lee H, Lee S, Heo Y . Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules. 2019; 24(6). PMC: 6470598. DOI: 10.3390/molecules24061190. View

Zak K, Grudnik P, Magiera K, Domling A, Dubin G, Holak T . Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure. 2017; 25(8):1163-1174. DOI: 10.1016/j.str.2017.06.011. View

Fessas P, Lee H, Ikemizu S, Janowitz T . A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017; 44(2):136-140. PMC: 5612055. DOI: 10.1053/j.seminoncol.2017.06.002. View

Huang Y, Xie W, Fan H, Du J . Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. Front Oncol. 2019; 9:972. PMC: 6779807. DOI: 10.3389/fonc.2019.00972. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View

Li J, Gu J . Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. Immunotherapy. 2018; 10(15):1293-1302. DOI: 10.2217/imt-2018-0116. View

10.

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

11.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

12.

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

13.

Jia M, Feng W, Kang S, Zhang Y, Shen J, He J . Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis. 2015; 7(3):455-61. PMC: 4387409. DOI: 10.3978/j.issn.2072-1439.2015.02.06. View

14.

Almutairi A, Alkhatib N, Martin J, Babiker H, Garland L, McBride A . Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Crit Rev Oncol Hematol. 2019; 142:16-25. DOI: 10.1016/j.critrevonc.2019.07.004. View

15.

Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L . Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget. 2017; 8(52):90215-90224. PMC: 5685743. DOI: 10.18632/oncotarget.21652. View

16.

Robert C, Ribas A, Schachter J, Arance A, Grob J, Mortier L . Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9):1239-1251. DOI: 10.1016/S1470-2045(19)30388-2. View

17.

Liu K, Tan S, Chai Y, Chen D, Song H, Zhang C . Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 2016; 27(1):151-153. PMC: 5223223. DOI: 10.1038/cr.2016.102. View

18.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

19.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

20.

Tan S, Liu K, Chai Y, Zhang C, Gao S, Gao G . Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2017; 9(1):135-139. PMC: 5777972. DOI: 10.1007/s13238-017-0412-8. View